Candel Therapeutics Q2 Net Loss $38.9M; Raises $117.7M Capital
Candel Therapeutics, Inc. reported a net loss of $38.9 million for the second quarter of 2026, with a diluted EPS of $(0.52). For the first six months of 2026, the company's net loss was $47.8 million, a significant increase from a net income of $2.6 million in the same period last year. Despite the losses, the company substantially strengthened its cash position, raising $93.5 million net from a public offering and an additional $24.2 million net through at-the-market offerings, bringing total cash and cash equivalents to $201.6 million as of June 30, 2026.
Key Highlights
- Reported Q2 2026 net loss of $38.9 million, with EPS of $(0.52).
- H1 2026 net loss was $47.8 million, compared to $2.6 million net income in H1 2025.
- Cash and cash equivalents increased to $201.6 million as of June 30, 2026.
- Raised $93.5 million net from a public offering in February 2026.
- Generated $24.2 million net from at-the-market offerings by June 30, 2026.
- Research and development expenses increased to $19.8 million in Q2 2026.
- Total liabilities increased to $82.0 million as of June 30, 2026.
- Warrant liabilities increased to $20.2 million as of June 30, 2026.
Price Impact
More from CADL
Candel Therapeutics Appoints Martine Zimmermann to Board of Directors
Candel Therapeutics Q2 Net Loss $38.9M; Plans Aglatimagene BLA Q4 2026
Candel Therapeutics Q2 Net Loss $38.9M; BLA Planned Q4 2026; Cash to Q1 2028